1-4 of 4
Shan Zeng
Close
Sort by
Journal Articles

Zanubrutinib Combined with R-CHOP in Previously Untreated Non-Germinal Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with BCL2 and MYC Protein Co-Expression: A Multicenter, Phase II Study

Jia Jin, Yalan Wang, Xi Wang, Yonghong Tang, Shan Zeng, Juan Du, Junning Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4468.
https://doi.org/10.1182/blood-2023-181529
Published: 2023
Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Qian Jiang, MD, Xiaojun Huang, MD, Zi Chen, MD, Qian Niu, MD, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, MD, Weiming Li, PhD, Xiaoli Liu, Na Xu, Yongping Song, MD, Yanli Zhang, Li Meng, MDPhD, Zhenya Hong, MDPhD, Bingcheng Liu, Shan Zeng, Lichuang Men, Yan Li, MD, Suning Chen, Mengxing Xue, PhD, Huanling Zhu, MD, He Li, Xin Du, Jin Lou, MD, Xiaohan Zhang, Yang Liang, MD, Yujun Dai, MD PhD, Ming Lu, PhD, Hengbang Wang, Jiao JI, PhD MD, Changai Yue, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142142
Published: 2020
Journal Articles

Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl)

Shan Zeng, Zhiheng Xu, Stan Lipkowitz, Jack B. Longley
Journal: Blood
Blood (2005) 105 (1): 226–232.
https://doi.org/10.1182/blood-2004-05-1768
Published: 2005
Journal Articles

The c- KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Yongsheng Ma, Shan Zeng, Dean D. Metcalfe, Cem Akin, Sasa Dimitrijevic, Joseph H. Butterfield, Gerald McMahon, B. Jack Longley
Journal: Blood
Blood (2002) 99 (5): 1741–1744.
https://doi.org/10.1182/blood.V99.5.1741
Published: 2002